Latest Biotron (ASX:BIT) News

Biotron Limited has completed the initial safety phase of its lead Hepatitis B drug in animal studies, paving the way for efficacy testing in two distinct mouse models. This milestone marks a significant step forward in the company’s antiviral drug development program.

Biotron Limited reported a robust net cash inflow of $1.095 million for the December 2024 quarter, driven largely by government grants, supporting its operational stability despite ongoing R&D expenses.

Biotron Limited has engaged US-based C14 Consulting Group to drive strategic partnerships for its antiviral drug portfolio, including lead candidate BIT225, while advancing its Hepatitis B research.